Press Releases

Press Releases

August 6, 2018

TEGSEDI™ (inotersen) Approved in European Union                 $382 million to fund the company through key milestones in 2019        Conference Call Webcast Monday, August 6 , 4:30 p.m. ET at www.akceatx.com CAMBRIDGE, Mass. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.

August 2, 2018

- PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea - SOUTH PLAINFIELD, N.J. and CAMBRIDGE, Mass. , Aug. 2, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), and Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.

July 31, 2018

Results from the first-ever study evaluating quality of life in people with FCS and impact of patient connectivity published in Expert Opinion on Orphan Drugs. Both active and passive connectivity associated with significant improvement in patient-reported perceptions of overall health, disease

July 23, 2018

Webcast scheduled for Monday, August 6th at 4:30 p.m. Eastern Time CAMBRIDGE, Mass. , July 23, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Monday, August 6 th at 4:30 p.m.

July 11, 2018

CAMBRIDGE, Mass. and CARLSBAD, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced today that TEGSEDI TM (inotersen) has received marketing authorization approval

July 5, 2018
-TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life- -Akcea prepared for launch following approval- CARLSBAD, Calif. , and CAMBRIDGE, Mass. , July 5, 2018 /PRNewswire/ --  Ionis Pharmaceuticals, Inc.
June 13, 2018

Results published in Expert Review of Cardiovascular Therapy CAMBRIDGE, Mass. , June 13, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat people with serious and rare diseases,

June 12, 2018

hATTR Compass to provide no-cost, confidential genetic testing and genetic counseling services, potentially enabling faster diagnosis CAMBRIDGE, Mass. , June 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.

June 5, 2018

CAMBRIDGE, Mass. , June 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Richard (Rich) A. Moscicki , M.D., to the Company’s Board of Directors. “Rich is an experienced, well-respected industry

June 1, 2018

CAMBRIDGE, Mass. and CARLSBAD, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the